The Distribution Policy is the supply-chain document. It explains who synthesises the peptide, who fills the pen, who tests the lot, who ships the parcel, and what the rules are for resale, counterfeits, institutional accounts and partnership inquiries. Read together with the Shipping Policy and the Refund Policy, it describes the operational backbone of the company.
ReadyPep is the authorized distributor of pre-filled, dial-an-aliquot research peptide pens manufactured by Metatide Healthcare. The relationship is a direct, written distribution arrangement between the two companies. ReadyPep does not synthesize the peptides, does not fill the pens, does not source from the grey market, does not relabel and does not repackage. Manufacturer paperwork, lot identifier, and primary product responsibility remain with Metatide Healthcare; ReadyPep operates the distribution layer.
The Metatide Healthcare wordmark is shown on the pen body, the manufacturer paperwork and the lot label exactly as the manufacturer renders it. ReadyPep does not cover, blur, alter, photoshop or otherwise obscure the manufacturer mark in product photography, in the warehouse, or in shipping. The ReadyPep mark appears only on the distributor paperwork, the parcel exterior, the order confirmation email and the storefront. It never appears on the pen itself.
Every lot ReadyPep distributes follows the same four-step pipeline. The pipeline is auditable by lot identifier from the storefront product page: each lot two third-party PDFs reference the manufacturer paperwork, and each Order confirmation references both the lot and the certificates.
Every lot has a third-party record on readypep.com, available to registered members, before the lot is sold to a Researcher. Researchers can verify the certificate before a purchase decision, not after, by reading the two PDFs linked from the product page. The PDFs are issued by the independent lab on the lab letterhead and are independent of any document ReadyPep or Metatide Healthcare produce.
After delivery, the same two PDFs are referenced on the order confirmation, on the parcel exterior label and on the certificate-of-analysis library at /lab-testing. The certificate library is the canonical, version-controlled record of every lot ReadyPep has distributed; it is also the record we work from when a researcher invokes the certificate guarantee in the Refund Policy.
From manufacturer outbound through third-party lab handling and UK warehouse storage to dispatch, each lot is handled to keep the peptide within the stability envelope published by the manufacturer. Orders are sealed in tamper-evident packaging, dispatched on an expedited service, and should be refrigerated by the Researcher on arrival (see section 02 of the Shipping Policy).
Packaging integrity is verified at each handoff. Tamper seals are applied at the warehouse and inspected at delivery. Where a tamper seal is broken at receipt, or the Order arrives damaged, it is treated as a shipping failure under the Refund Policy and replaced free of charge.
Products distributed by ReadyPep are sold strictly to qualified Researchers for in-vitro laboratory work. Resale, redistribution, repackaging, relabelling, listing on consumer marketplaces or social-media DM channels, or onward transfer to a non-Researcher consumer is forbidden as a condition of sale. The eligibility attestation in the Terms of Service is the operative restriction; this section is the supply-chain corollary.
Where ReadyPep identifies a counterfeit, diverted or repackaged listing of a Metatide Healthcare-branded pen on a third-party marketplace, social-media account or storefront, ReadyPep coordinates with Metatide Healthcare on a takedown notice. Where the listing references a real lot identifier, ReadyPep also flags the underlying Order and the Researcher Account that originated the lot for review.
Counterfeit listings (whether they reference Metatide Healthcare, ReadyPep, a real lot identifier, or a fabricated identifier) should be reported to [email protected] with a screenshot and the listing URL. ReadyPep maintains an internal counterfeit register, files takedown notices with the marketplace operator on Metatide Healthcare behalf, and publishes a quarterly summary of takedowns at /lab-testing for transparency.
Researchers who buy what they believed to be a Metatide Healthcare-branded pen from a non-ReadyPep channel and discover the lot does not match a published third-party certificate are encouraged to report through the same channel. ReadyPep cannot honour the certificate guarantee on third-party purchases, but the report helps the takedown effort and is appreciated.
ReadyPep distributes worldwide to qualified Researchers, except to the destinations on the no-ship list published in the Shipping Policy. Inclusion on the no-ship list is driven by sanctions, customs rules, courier capacity, and local-law restrictions on receipt of research peptides. The no-ship list is updated as those constraints evolve and is honoured at the Order-confirmation step.
Where a Researcher destination is on the screened list rather than the no-ship list, ReadyPep may request additional documentation (for example, an institutional letter, an end-use statement, or a research-use exclusion declaration) before the Order ships. The screening exists to satisfy customs and the carrier, not to obstruct the Researcher.
Bulk and institutional accounts are accepted on application to [email protected]. The application requires the institution legal name, registered address, the named Researcher role, the institution research-use letter, and the expected order cadence. Approved institutional accounts may be granted bulk pricing, net-terms billing, and direct-courier-account billing at the institution election.
Reseller-style accounts (that is, accounts that propose to redistribute ReadyPep-supplied pens to onward Researchers) are not granted as a default. The default is a single-Researcher or single-institution account. Where Metatide Healthcare authorises ReadyPep to operate a reseller relationship for a specific jurisdiction, the relationship is documented in writing, the reseller is listed publicly at /lab-testing, and the reseller is bound to the same eligibility, attestation and distribution terms that apply to direct researchers.
Press inquiries (interviews, fact-checking, embargoed access to a new lot certificate, public-facing partnership announcements) are handled through [email protected]. ReadyPep responds to press inquiries within two (2) UK business days during normal news cycles.
Lab partnership inquiries (for example, an analytical laboratory proposing an additional independent test, a journal proposing a method-development collaboration, or a contract-research organisation proposing a study reference standard) are handled through [email protected]. We respond within five (5) UK business days.
The arrangement between ReadyPep and Metatide Healthcare is reviewed annually. Material changes (for example, addition of a manufacturing site, addition of a second testing lab, change of the courier set, or a change to the distribution territory) are signposted on the Site at /lab-testing and at /about, and material changes that affect Researcher rights under any other policy in this set (Terms of Service, Privacy, Shipping, Refund) are notified by email to all Account holders at least fourteen (14) days before they take effect.
Every lot ReadyPep distributes follows the same four-step pipeline. The pipeline is auditable by lot identifier from the storefront product page: each lot two third-party PDFs reference the manufacturer paperwork, and each Order confirmation references both the lot and the certificates.
Every lot has a third-party record on readypep.com, available to registered members, before the lot is sold to a Researcher. Researchers can verify the certificate before a purchase decision, not after, by reading the two PDFs linked from the product page. The PDFs are issued by the independent lab on the lab letterhead and are independent of any document ReadyPep or Metatide Healthcare produce.
After delivery, the same two PDFs are referenced on the order confirmation, on the parcel exterior label and on the certificate-of-analysis library at /lab-testing. The certificate library is the canonical, version-controlled record of every lot ReadyPep has distributed; it is also the record we work from when a researcher invokes the certificate guarantee in the Refund Policy.
From manufacturer outbound through third-party lab handling and UK warehouse storage to dispatch, each lot is handled to keep the peptide within the stability envelope published by the manufacturer. Orders are sealed in tamper-evident packaging, dispatched on an expedited service, and should be refrigerated by the Researcher on arrival (see section 02 of the Shipping Policy).
Packaging integrity is verified at each handoff. Tamper seals are applied at the warehouse and inspected at delivery. Where a tamper seal is broken at receipt, or the Order arrives damaged, it is treated as a shipping failure under the Refund Policy and replaced free of charge.
Products distributed by ReadyPep are sold strictly to qualified Researchers for in-vitro laboratory work. Resale, redistribution, repackaging, relabelling, listing on consumer marketplaces or social-media DM channels, or onward transfer to a non-Researcher consumer is forbidden as a condition of sale. The eligibility attestation in the Terms of Service is the operative restriction; this section is the supply-chain corollary.
Where ReadyPep identifies a counterfeit, diverted or repackaged listing of a Metatide Healthcare-branded pen on a third-party marketplace, social-media account or storefront, ReadyPep coordinates with Metatide Healthcare on a takedown notice. Where the listing references a real lot identifier, ReadyPep also flags the underlying Order and the Researcher Account that originated the lot for review.
Counterfeit listings (whether they reference Metatide Healthcare, ReadyPep, a real lot identifier, or a fabricated identifier) should be reported to [email protected] with a screenshot and the listing URL. ReadyPep maintains an internal counterfeit register, files takedown notices with the marketplace operator on Metatide Healthcare behalf, and publishes a quarterly summary of takedowns at /lab-testing for transparency.
Researchers who buy what they believed to be a Metatide Healthcare-branded pen from a non-ReadyPep channel and discover the lot does not match a published third-party certificate are encouraged to report through the same channel. ReadyPep cannot honour the certificate guarantee on third-party purchases, but the report helps the takedown effort and is appreciated.
ReadyPep distributes worldwide to qualified Researchers, except to the destinations on the no-ship list published in the Shipping Policy. Inclusion on the no-ship list is driven by sanctions, customs rules, courier capacity, and local-law restrictions on receipt of research peptides. The no-ship list is updated as those constraints evolve and is honoured at the Order-confirmation step.
Where a Researcher destination is on the screened list rather than the no-ship list, ReadyPep may request additional documentation (for example, an institutional letter, an end-use statement, or a research-use exclusion declaration) before the Order ships. The screening exists to satisfy customs and the carrier, not to obstruct the Researcher.
Bulk and institutional accounts are accepted on application to [email protected]. The application requires the institution legal name, registered address, the named Researcher role, the institution research-use letter, and the expected order cadence. Approved institutional accounts may be granted bulk pricing, net-terms billing, and direct-courier-account billing at the institution election.
Reseller-style accounts (that is, accounts that propose to redistribute ReadyPep-supplied pens to onward Researchers) are not granted as a default. The default is a single-Researcher or single-institution account. Where Metatide Healthcare authorises ReadyPep to operate a reseller relationship for a specific jurisdiction, the relationship is documented in writing, the reseller is listed publicly at /lab-testing, and the reseller is bound to the same eligibility, attestation and distribution terms that apply to direct researchers.
Press inquiries (interviews, fact-checking, embargoed access to a new lot certificate, public-facing partnership announcements) are handled through [email protected]. ReadyPep responds to press inquiries within two (2) UK business days during normal news cycles.
Lab partnership inquiries (for example, an analytical laboratory proposing an additional independent test, a journal proposing a method-development collaboration, or a contract-research organisation proposing a study reference standard) are handled through [email protected]. We respond within five (5) UK business days.
The arrangement between ReadyPep and Metatide Healthcare is reviewed annually. Material changes (for example, addition of a manufacturing site, addition of a second testing lab, change of the courier set, or a change to the distribution territory) are signposted on the Site at /lab-testing and at /about, and material changes that affect Researcher rights under any other policy in this set (Terms of Service, Privacy, Shipping, Refund) are notified by email to all Account holders at least fourteen (14) days before they take effect.
All six documents form one binding agreement between ReadyPep and every researcher with a ReadyPep account or order on file.